ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year
Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform Advanced Lead Candidates for COVID-19 PolyTope™ Cocktail Therapy, Preclinical Trials Scheduled to Launch in January 2021 VICTORIA, BC, Dec. 21, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) today announced financial results for the second quarter of its 2021 fiscal year ended October 31, 2020. Q2 Fiscal 2021 Financial Highlights: Revenue was $4.8 million for the quarter ended October 31, 2020, an increase of $1.6 million,...
Source: newswire.ca